From: Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
study | Treatment (μg) | Number of subjects | Duration (weeks) | Key inclusion criteria | Male (%) | Mean age (years) | Baseline FEV1 (%predicted) |
---|---|---|---|---|---|---|---|
Donohue 2002 | Tiotoropium 18 Salmeterol 100 | 623 | 24 | %FEV1 < 60% >  40 yrs., > 10PY | 74.6 | 64.0 | 40.2 |
Brusasco 2003 | Tiotoropium 18 Salmeterol 100 | 807 | 24 | %FEV1 ≤ 65%, >  40 yrs., > 10PY | 76.2 | 64.0 | 42.9 |
Briggs 2005 | Tiotoropium 18 Salmeterol 100 | 653 | 12 | %FEV1 < 60%, >  40 yrs., > 10PY | 66.4 | 64.4 | 37.7 |
Buhl 2011 INTENSITY study | Tiotoropium 18 Indacaterol 150 | 1598 | 12 | %FEV1 30–80%, >  40 yrs., > 10PY | 69.0 | 63.5 | 54.4 |
Vogelmeier 2011 POET study | Tiotoropium 18 Salmeterol 100 | 7376 | 52 | %FEV1 ≤ 70%, ≥ 40 yrs., ≥ 10PY, Ex (+) | 74.6 | 62.9 | 49.3 |
Bateman 2013 SHINE study | Glycopyrronium 50a Indacaterol 150a | 1435 | 26 | %FEV1 ≥ 30%, <  80% ≥ 40 yrs., ≥ 10PY | 75.4 | 63.9 | 53.7 |
Decramer 2013 INVIGORATE | Tiotoropium 18 Indacaterol 150 | 3439 | 52 | %FEV1 > 30%, ≤ 50% ≥ 40 yrs., ≥ 10PY, Ex (+) | 77.0 | 64.0 | 40.5 |
Donohue 2013 | Umeclidinium 62.5a Vilanterol 25a | 839 | 24 | %FEV1 ≤ 70% mMRC ≥2, ≥ 40 yrs., ≥ 10PY | 69.0 | 63.3 | 47.5 |
Celli 2014 | Umeclidinium 125a Vilanterol 25a | 811 | 24 | %FEV1 ≤ 70% mMRC ≥2, ≥ 40 yrs., ≥ 10PY | 66.0 | 63.0 | 48.7 |
Decramer 2014 | Tiotoropium 18a Vilanterol 25a | 417 | 24 | %FEV1 ≤ 70% mMRC ≥2, ≥ 40 yrs., ≥ 10PY | 68.0 | 62.9 | 47.7 |
D’Urzo 2014 AUGMENT study | Aclidinium 800a Formoterol 24a | 669 | 24 | %FEV1 ≥ 30%, <  80% mMRC ≥2, ≥ 40 yrs., > 10PY | 56.0 | 64.2 | 53.3 |
Singh 2014 ACLIFORM-COPD | Aclidinium 800a Formoterol 24a | 769 | 24 | %FEV1 < 70% mMRC ≥2, ≥ 40 yrs., > 10PY | 66.5 | 63.2 | 54.0 |
Buhl 2015 TOnado 1 and 2 | Tiotoropium 2.5/5a Olodaterol 5a | 2071 | 52 | %FEV1 > 30%, <  80% mMRC ≥2, ≥ 40 yrs., > 10PY | 73.4 | 64.1 | 50.0 |
Mahler 2015 FLIGHT1 and 2 | Glycopyrrolate 31.2a Indacaterol 55a | 1022 | 12 | %FEV1 > 30%, <  80% mMRC ≥2, ≥ 40 yrs., > 10PY | 64.8 | 63.6 | 54.5 |
Mahler 2016 GEM3 study | glycopyrrolate 31.2 Indacaterol 75 | 511 | 52 | %FEV1 ≥ 30%, <  80% mMRC> 2, ≥ 40 yrs., ≥ 10PY | 57.2 | 63.2 | 53.1 |
D’Urzo 2017 AUGMENT study | Aclidinium 800a Formoterol 24a | 669 | 52 | %FEV1 ≥ 30%, <  80% ≥ 40 yrs., ≥ 10PY | 56.0 | 64.2 | 53.3 |
Hanania 2017 PINNACLE-3 | Glycopyrronium 36a Formoterol 19.2a | 1772 | 52 | %FEV1 ≥ 30%, <  80% or %FEV1 < 30% & FEV1 ≥ 750 ml, 40–80 yrs | 55.8 | 62.8 | 51.3 |
Martinez 2017 PINNACLE-1, −2 | Glycopyrronium 36a Formoterol 19.2a | 1776 | 24 | %FEV1 ≥ 30%, <  80% or %FEV1 < 30% & FEV1 ≥ 750 ml, 40–80 yrs | 55.8 | 62.8 | 51.3 |
Lipworth 2018 PINNACLE-4 | Glycopyrronium 36a Formoterol 19.2a | 954 | 24 | %FEV1 < 80% 40–80 yrs., ≥ 10PY | 74.1 | 64.1 | 54.4 |